Nature Reviews Cancer (2018) https://doi.org/10.1038/s41568-018-0009-4 Published online 25 April 2018
In the online html version of this article, the affiliations for Jessica L. Pettigrew and John C. Bell were not correct. Jessica L. Pettigrew is at the Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada and John C. Bell is at the Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. This is correct in the print and PDF versions of the article and has been corrected in the html version.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Twumasi-Boateng, K., Pettigrew, J.L., Kwok, Y.Y.E. et al. Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 18, 526 (2018). https://doi.org/10.1038/s41568-018-0019-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-018-0019-2
This article is cited by
-
Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies
Annals of Hematology (2024)
-
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment
Experimental Hematology & Oncology (2023)
-
Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
Signal Transduction and Targeted Therapy (2023)
-
Polymer-based synthetic oncolytic virus-like nanoparticles for cancer immunotherapy
Science China Chemistry (2023)
